Exacis Biotherapeutics, Inc. announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis’ innovative, iPSC-derived mRNA-engineered natural killer cell products to treat cancer.
[Exacis Biotherapeutics, Inc. (PR Newswire, Inc.)]
7992332
{7992332:nan}
apa
50
1
168471
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
